Exclusive Summary

• - Targets a very large CKD population: ~700 million globally, with 70–140 million non-dialysis stage 3–5 potential candidates.
• - Unique non-systemic MOA: AST-120 class adsorbent complements RAAS and SGLT2 therapy with low DDI risk and favorable safety.
• - Competition concentrated in East Asia: approved in JP/KR/TW/TH, with little to no availability elsewhere, enabling regional differentiation.
• - Strong quality and registration footing: KR-MFDS GMP, API compliant with BP/USP/EP/Ph.Int., and proven registration in Korea.
• - Cost and convenience: 2 g sachet/granule reduces pill burden and typically offers 30–60% cost savings versus the originator.

Asset Materials

Contact Us for Full Materials